Compare GEHC & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEHC | WAT |
|---|---|---|
| Founded | 1892 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9B | 33.5B |
| IPO Year | 2022 | 1996 |
| Metric | GEHC | WAT |
|---|---|---|
| Price | $64.31 | $417.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 17 |
| Target Price | $88.38 | ★ $379.19 |
| AVG Volume (30 Days) | ★ 2.6M | 608.4K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.24% | N/A |
| EPS Growth | ★ 4.84 | 0.47 |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $20,625,000,000.00 | N/A |
| Revenue This Year | $7.12 | $104.66 |
| Revenue Next Year | $4.45 | $10.40 |
| P/E Ratio | $75.38 | ★ N/A |
| Revenue Growth | ★ 4.84 | N/A |
| 52 Week Low | $58.75 | $282.77 |
| 52 Week High | $89.77 | $426.22 |
| Indicator | GEHC | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 35.13 | 51.37 |
| Support Level | $60.17 | $372.33 |
| Resistance Level | $65.83 | $426.22 |
| Average True Range (ATR) | 1.48 | 10.34 |
| MACD | -1.10 | -2.07 |
| Stochastic Oscillator | 18.35 | 40.35 |
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.